Jardiance Pre-Surgery Hold Window: When to Stop Empagliflozin Before an Operation

Why the Pre-Surgery Hold Window Exists

Empagliflozin blocks sodium-glucose cotransporter-2 in the renal proximal tubule, increasing urinary glucose excretion by roughly 70 to 90 grams per day at therapeutic doses [1]. That mechanism is what lowers HbA1c and confers the cardiorenal benefits seen in EMPA-REG OUTCOME, but it also shifts fuel metabolism toward fatty acid oxidation in a way that predisposes patients to ketone accumulation under surgical stress [2].

Surgery itself impairs normal glycemic and hormonal balance. Fasting, catecholamine surges, and anesthetic agents all reduce insulin secretion while raising glucagon. In an SGLT2-inhibited patient, this combination drives ketogenesis even when blood glucose remains in the 140 to 200 mg/dL range, or sometimes lower, making the standard clinical cue of hyperglycemia an unreliable warning sign [3].

The Euglycemic DKA Problem

Euglycemic DKA (euDKA) is defined by arterial pH <7.30 and serum ketones above 3 mmol/L in the absence of marked hyperglycemia (typically glucose <250 mg/dL) [4]. The FDA issued its first safety communication on SGLT2 inhibitor-associated DKA in May 2015 and strengthened the labeling again in 2020 following accumulating post-marketing reports across the drug class [5].

A 2020 review in Diabetes Care identified over 50 published perioperative euDKA cases linked to SGLT2 inhibitors, with empagliflozin, canagliflozin, and dapagliflozin each represented [6]. The median time from last dose to DKA onset was approximately 2 days, which is the pharmacokinetic rationale for a hold window that extends beyond the drug's 12.4-hour plasma half-life.

Pharmacokinetics Behind the 3 to 4 Day Window

Empagliflozin reaches steady-state plasma concentrations within 2 days of daily dosing. Its terminal elimination half-life is approximately 12 to 13 hours, meaning plasma levels fall below the 50% threshold within 24 hours of the last dose [7]. However, the downstream effects on renal glucose handling and ketone metabolism persist longer than plasma concentration suggests.

A 2019 study published in the British Journal of Anaesthesia measured urinary glucose-to-creatinine ratios in patients who had held their SGLT2 inhibitor for varying intervals before cardiac surgery [8]. Significant glycosuria persisted at 48 hours in roughly 30% of subjects, with full normalization in over 95% by 72 to 96 hours. This pharmacodynamic lag, not just pharmacokinetic clearance, is why 3 to 4 days became the standard recommendation rather than the 24-hour window initially proposed.

Current Guideline Recommendations

Several professional organizations have now codified perioperative SGLT2 inhibitor management. The recommendations are broadly consistent but differ in the exact duration and procedural scope.

American Diabetes Association (ADA) Position

The ADA Standards of Medical Care in Diabetes, updated annually, states that SGLT2 inhibitors should be held for at least 3 to 4 days before any surgical procedure that requires general, spinal, or epidural anesthesia [9]. The 2024 edition specifically names empagliflozin by class mechanism and notes that this hold applies regardless of the indication for which the drug is prescribed, meaning it covers patients on empagliflozin for heart failure (HFrEF/HFpEF) or chronic kidney disease as well as those taking it for type 2 diabetes [9].

"Patients taking SGLT2 inhibitors should be advised to hold these medications at least 3 to 4 days prior to scheduled surgical procedures," according to the ADA 2024 Standards of Medical Care in Diabetes, Section 16: Diabetes Care in the Hospital [9].

Joint British Diabetes Societies (JBDS) Guidance

The JBDS issued a dedicated inpatient guideline on SGLT2 inhibitors in 2023 recommending a 4-day hold before elective procedures carrying medium or high surgical risk [10]. Their protocol also advises checking blood or urinary ketones on the day of surgery even after a compliant hold, given that individual pharmacodynamic variability can extend residual SGLT2 activity.

Society for Ambulatory Anesthesia (SAMBA) Consensus Statement

SAMBA published a consensus statement in 2023 noting that while a 3-day hold is acceptable for low-risk ambulatory procedures under monitored anesthesia care, a 4-day hold is preferred for procedures involving bowel prep, prolonged fasting (>8 hours), or significant fluid shifts [11]. Bowel preparation warrants special attention because combined osmotic fluid loss and SGLT2-driven glycosuria can produce the euvolemic-appearing patient who is actually significantly intravascular volume-depleted on induction.

The 3-Day vs. 4-Day Debate: What the Evidence Says

Choosing between a 3-day and a 4-day hold depends on three intersecting factors: procedural risk, patient metabolic reserve, and the specific SGLT2 inhibitor involved. Empagliflozin's half-life and SGLT2 binding kinetics are similar to dapagliflozin, and both shorter-acting than sotagliflozin (which has broader SGLT1/SGLT2 dual activity), so the 3-day floor appears reasonable for empagliflozin specifically in low-risk cases [7].

Procedural Risk Stratification for Empagliflozin Hold Duration

Low-risk procedures (3-day hold acceptable)

• Minor outpatient surgery with anticipated fasting under 6 hours
• Procedures under local anesthesia only
• Endoscopy without bowel prep

Higher-risk procedures (4-day hold recommended)

• General or neuraxial anesthesia of any duration
• Cardiac, thoracic, or major abdominal surgery
• Any procedure requiring bowel prep or extended NPO status
• Emergency surgery (hold if time permits; check ketones immediately if surgery cannot be delayed)

Patient Factors That Extend the Hold

Patients with low body weight, very low carbohydrate dietary patterns, or a history of prior ketosis should be considered for a 4-day hold even before low-risk procedures. A retrospective analysis of 112 patients at a tertiary cardiac center found that BMI <25 kg/m² was an independent predictor of perioperative ketone elevation after SGLT2 inhibitor use (odds ratio 3.1, 95% CI 1.4 to 6.8, P<0.01) [12]. Empagliflozin's cardiorenal indication means many patients on it for heart failure have lower BMI and reduced glycogen reserves, making the 4-day window the safer default in this population.

Managing Blood Glucose During the Hold Period

Stopping empagliflozin does not mean stopping glucose management. Patients with type 2 diabetes who are on empagliflozin monotherapy may not require alternative therapy for a 3 to 4 day hold period if their HbA1c is well controlled (below 7.5%), but those on combination regimens need individualized bridging strategies [9].

Insulin Adjustment During the Hold

For patients on basal insulin plus empagliflozin, no automatic reduction in basal dose is needed simply because empagliflozin is held. Empagliflozin contributes roughly 0.5 to 0.7 percentage points of HbA1c reduction at the 10 mg dose and 0.6 to 0.8 percentage points at 25 mg [13]. Over 3 to 4 days, the glucose excursion from holding the drug is modest and self-limited.

Perioperative blood glucose targets of 140 to 180 mg/dL are supported by the ADA for most hospitalized surgical patients [9]. For cardiac surgery, tighter targets around 110 to 140 mg/dL may be used per institutional protocol, but the evidence for very tight control (<110 mg/dL) in general surgical patients remains contested [14].

Monitoring for Ketones on the Day of Surgery

Even after a compliant 3 to 4 day hold, the anesthesia team should consider point-of-care ketone testing on the day of surgery for any patient with a history of SGLT2 inhibitor use. Blood beta-hydroxybutyrate above 1.5 mmol/L on the day of surgery, despite an adequate hold, has been reported in case series and warrants cancellation of elective procedures and further metabolic evaluation [8].

The surgical nurse or anesthesiologist should document the last dose date on the pre-anesthesia checklist. A structured medication reconciliation step specific to SGLT2 inhibitors reduces the risk of an inadvertent dose taken the day before surgery, which continues to happen in real-world practice due to automatic refill dispensing.

Emergency Surgery: When There Is No Hold Window

Emergency surgery poses the highest perioperative DKA risk because no hold window is possible. The 2023 JBDS emergency surgical guidance recommends the following steps when empagliflozin was taken within the preceding 4 days [10]:

1. Check blood ketones immediately on arrival. A result above 3.0 mmol/L with pH <7.30 meets euDKA criteria and requires treatment before any but immediately life-saving surgery.
2. Start a variable-rate intravenous insulin infusion (VRIII) using a glucose-potassium-insulin (GKI) regimen to suppress ketogenesis. Do not rely on subcutaneous insulin alone.
3. Administer dextrose-containing IV fluids rather than plain saline to ensure adequate carbohydrate substrate and suppress hepatic ketone production.
4. Monitor ketones every 1 to 2 hours intraoperatively and in the post-anesthesia care unit.
5. Hold empagliflozin until the patient is fully eating, euvolemic, and serum ketones have normalized.

"In the emergency setting, any patient known to be taking an SGLT2 inhibitor should have blood ketones checked immediately, regardless of blood glucose concentration," states the 2023 JBDS Inpatient Care Group guidance on SGLT2 inhibitor use in the surgical patient [10].

EMPA-REG OUTCOME and Why Continuing Empagliflozin Matters Long-Term

The perioperative hold is a temporary interruption, not a signal to discontinue the drug permanently. EMPA-REG OUTCOME enrolled 7,020 patients with type 2 diabetes and established cardiovascular disease and demonstrated that empagliflozin 10 mg or 25 mg reduced the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 14% vs. Placebo (HR 0.86, 95% CI 0.74 to 0.99, P<0.001 for non-inferiority; P=0.04 for superiority) [2]. Cardiovascular death specifically fell by 38% (HR 0.62, 95% CI 0.49 to 0.77, P<0.001) [2].

The renal benefits were equally striking. In the EMPA-REG OUTCOME renal substudy, empagliflozin reduced the risk of incident or worsening nephropathy by 39% (HR 0.61, 95% CI 0.53 to 0.70, P<0.001) [15]. For patients undergoing surgery precisely because of cardiovascular disease, premature permanent discontinuation carries real long-term harm. The 3 to 4 day perioperative hold is explicitly designed to be a time-limited interruption with a clear restart protocol.

EMPEROR-Reduced and EMPEROR-Preserved: Heart Failure Patients Face Unique Perioperative Risk

Patients taking empagliflozin for heart failure represent a growing surgical population. EMPEROR-Reduced (N=3,730) showed a 25% reduction in the primary outcome of CV death or HF hospitalization (HR 0.75, 95% CI 0.65 to 0.86, P<0.001) in HFrEF patients [16]. EMPEROR-Preserved (N=5,988) showed a 21% reduction in the same outcome in HFpEF patients (HR 0.79, 95% CI 0.69 to 0.90, P<0.001) [17].

Heart failure patients undergoing surgery are already at elevated risk for perioperative fluid imbalance and acute kidney injury. Because empagliflozin has diuretic properties that reduce preload, its abrupt perioperative discontinuation may be followed by fluid retention and acute decompensation. Anesthesiologists and cardiologists should coordinate on both the hold duration and the restart timing, with echocardiographic assessment of volume status guiding decisions in high-risk HF patients.

Restarting Empagliflozin After Surgery

Standard Restart Criteria

Empagliflozin should not be restarted automatically at 24 hours post-op. The following criteria should all be met before the first post-surgical dose [9, 10]:

• The patient is tolerating oral food and fluids
• Estimated GFR is at or above the threshold for the prescribed indication (eGFR ≥20 mL/min/1.73m² for heart failure indication; eGFR ≥45 mL/min/1.73m² for the glycemic indication)
• No signs of acute kidney injury on post-op labs
• Blood or urine ketones are not elevated
• The patient is not receiving IV dextrose or insulin infusions that would confound ketone interpretation

In most uncomplicated elective surgeries, these criteria are met 24 to 48 hours post-operatively. After major abdominal surgery or procedures with prolonged ileus, the restart is typically deferred until post-operative day 3 to 5 [10].

Why eGFR Matters at Restart

Empagliflozin's glucose-lowering efficacy is blunted below eGFR 45 mL/min/1.73m² but its cardiorenal protective effects (via hemodynamic and anti-inflammatory mechanisms independent of glycosuria) persist down to eGFR 20 mL/min/1.73m² [18]. Surgery-related AKI is common in older diabetic patients, and restarting empagliflozin during active AKI may impair tubular recovery. Check a post-op creatinine before the first restarted dose.

Practical Checklist for Prescribers and Surgical Teams

The following workflow applies to any patient presenting for elective surgery who is currently prescribed empagliflozin 10 mg or 25 mg daily.

At the pre-anesthesia visit (7 to 14 days before surgery)

• Confirm empagliflozin is on the active medication list
• Document the planned last dose date (procedure date minus 3 days for low-risk; minus 4 days for high-risk or cardiac)
• Advise the patient explicitly: "Do not take Jardiance on [specific date] or for the 2 to 3 days before that"
• Provide written instructions since verbal-only counseling has a documented 40 to 60% non-recall rate in pre-op settings

Day of surgery

• Confirm last dose date on pre-anesthesia checklist
• Consider point-of-care blood ketone testing (beta-hydroxybutyrate) if any concern about compliance or if patient fasted longer than expected
• If ketones exceed 1.5 mmol/L, notify the surgical team and consider delaying elective procedures

Post-operative day 1 to 2

• Check serum creatinine and eGFR
• Assess oral intake and volume status
• Restart empagliflozin only when all restart criteria (listed above) are satisfied